Qian Zhongrun, Yang Dianxu, Sun Fei, Sun Zhenguo
a Department of Neurosurgery , Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University , Shanghai , China.
b Department of Neurosurgery , The Affiliated Xuzhou Hospital of Medical College of Southeast University , Xuzhou , Jiangsu , China.
Br J Neurosurg. 2017 Feb;31(1):84-88. doi: 10.1080/02688697.2016.1260686. Epub 2016 Nov 30.
Chronic subdural hematomas (CSDHs) are often found in neurosurgery, and display a recurrence rate of up to 37%. This study aimed to determine potential risk factors contributing to unilateral CSDH recurrence, and evaluate the role of postoperative management with dexamethasone (DX) in reducing recurrence.
Between January 2010 and May 2015, a total of 242 consecutive patients with CSDH treated with burr-hole trephination were included in this study. Univariate and multivariate analyses were performed to determine risk factors potentially associated with the recurrence of CSDH. Then, patients at high risk were divided into DX and non-DX treatment groups, respectively. Chi-square test was used to assess the potential role of DX.
CSDH recurrence was recorded in 39 patients (16.1%). Among various risk factors, advanced age (p = .01), preoperative midline displacement exceeding 10 mm (p < .001), and hematomas presenting with separated type (p = .03) were significantly associated with CSDH recurrence. Interestingly, patients who accepted therapy with DX had a lower rate of second drainage procedure (p = .017). In addition, DX effectively reduced disease recurrence in patients with the separated type of hematoma (p = .047), and seemed to be beneficial to those with advanced age and midline shift exceeding 10 mm, although statistical significance was not achieved.
These findings indicated that advanced age, midline displacement, and mixed density hematoma are independent factors for unilateral CSDH recurrence. When the above factors are detected in patients, additional DX administration should be recommended after operation.
慢性硬膜下血肿(CSDH)在神经外科中较为常见,其复发率高达37%。本研究旨在确定导致单侧CSDH复发的潜在风险因素,并评估术后使用地塞米松(DX)治疗在降低复发率方面的作用。
2010年1月至2015年5月期间,本研究共纳入242例连续接受钻孔引流治疗的CSDH患者。进行单因素和多因素分析以确定可能与CSDH复发相关的风险因素。然后,将高危患者分别分为DX治疗组和非DX治疗组。采用卡方检验评估DX的潜在作用。
39例患者(16.1%)出现CSDH复发。在各种风险因素中,高龄(p = 0.01)、术前中线移位超过10 mm(p < 0.001)以及血肿呈分隔型(p = 0.03)与CSDH复发显著相关。有趣的是,接受DX治疗的患者二次引流手术率较低(p = 0.017)。此外,DX有效降低了分隔型血肿患者的疾病复发率(p = 0.047),对于高龄和中线移位超过10 mm的患者似乎也有益处,尽管未达到统计学显著性。
这些发现表明,高龄、中线移位和混合密度血肿是单侧CSDH复发的独立因素。当在患者中检测到上述因素时,建议术后额外给予DX治疗。